Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
Open Access
- 28 March 2010
- Vol. 2 (4) , 826-866
- https://doi.org/10.3390/v2040826
Abstract
Hepatitis C virus (HCV) represents a major health burden, with an estimated 180 million chronically infected individuals worldwide. These patients are at increased risk of developing liver cirrhosis and hepatocellular carcinoma. Infection with HCV is the leading cause of liver transplantation in the Western world. Currently, the standard of care (SoC) consists of pegylated interferon alpha (pegIFN-α) and ribavirin (RBV). However this therapy has a limited efficacy and is associated with serious side effects. Therefore more tolerable, highly potent inhibitors of HCV replication are urgently needed. Both Specifically Targeted Antiviral Therapy for HCV (STAT-C) and inhibitors that are believed to interfere with the host-viral interaction are discussed.Keywords
This publication has 148 references indexed in Scilit:
- The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus ReplicationJournal of Biological Chemistry, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Treatment failure in hepatitis C: Mechanisms of non-responseJournal of Hepatology, 2008
- Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479Antimicrobial Agents and Chemotherapy, 2008
- Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of ResistanceAntimicrobial Agents and Chemotherapy, 2008
- Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796Antimicrobial Agents and Chemotherapy, 2008
- NS3 helicase actively separates RNA strands and senses sequence barriers ahead of the opening forkProceedings of the National Academy of Sciences, 2007
- An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: Synthesis and in vitro screening of 4-carbamoyl-5-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2-yl)imidazole-1-β-d-ribofuranosideBioorganic & Medicinal Chemistry Letters, 2007
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Structural biology of hepatitis C virusHepatology, 2004